A20 / A20-luc Orthotopic Mouse Model Service for Lymphoma

The A20 / A20-luc orthotopic mouse model disseminates a CD19/CD20-positive murine B-cell lymphoma through the hematolymphoid system of immunocompetent BALB/c mice — seeding bone marrow, spleen, liver, and lymph nodes, with a characteristic late meningeal invasion — inside a fully functional immune system. Alfa Cytology delivers this benchmark syngeneic platform with flexible inoculation configurations (subcutaneous, intravenous, or intraperitoneal), cyclophosphamide-preconditioned or irradiation-preconditioned designs for cell therapy studies, quantitative luciferase imaging in vivo, and toxicity-aware monitoring including cytokine panels and hind-limb-paralysis surveillance, so checkpoint antibodies, CAR constructs, bispecifics, vaccines, and in situ CAR strategies are evaluated under realistic immunological conditions.

Overview of A20 / A20-luc Orthotopic Mouse Model for Lymphoma

A20 is a BALB/c B-cell lymphoma line derived from a spontaneous reticulum cell neoplasm found in an aged BALB/cAnN mouse and characterized by Kim and colleagues in the Journal of Immunology in 1979; it has since become one of the most heavily used syngeneic tumor models in existence. The cells are suspension lymphoblasts with an 18-hour doubling time, a near-diploid karyotype (modal chromosome number 37), and a complete B-cell identity: surface immunoglobulin, CD19, CD20, Fc receptors, and MHC class I and II of the H-2^d haplotype, with professional antigen-presenting capability. Molecular cytogenetic analysis has mapped A20's rearrangement pattern onto the human genome and supports its interpretation as a sporadic Burkitt-type lymphoma model, while its ENCODE-project annotation and four decades of immunological use give it unusual experimental pedigree. Critically, A20 tumors are embedded in a partially immunosuppressive but fully immunocompetent microenvironment: they express PD-L1, secrete IL-10 and TGF-β, and recruit regulatory T cells and macrophages — precisely the biology that makes checkpoint blockade, combination regimens, and cell therapies testable in vivo.

Fig 1. Standard A20-luc model protocol showing ventral and dorsal bioluminescence imaging (1 min exposure, constant ROI) of BALB/c mice bearing systemic A20-Luc-GFP lymphoma established by IV injection of 5×10⁵ cells after 100 mg/kg cyclophosphamide preconditioning, with weekly total-flux quantification and survival tracking after CAR T cell infusion. (Kueberuwa, Gray, et al., 2018)

For lymphoma, orthotopic modeling means systemic hematolymphoid seeding, and A20 performs it faithfully. Subcutaneous flank inoculation (2 × 10⁵–5 × 10⁶ cells) establishes benchmark tumors; intravenous delivery (5 × 10⁵–10⁶ cells, classically after 100–200 mg/kg cyclophosphamide preconditioning) produces systemic disease in 7–14 days with dissemination to bone marrow, liver, spleen, lymph nodes, ovaries, and peritoneal cavity — and, distinctively, meningeal invasion that can manifest as hind-limb paralysis and must be monitored as a humane-endpoint signal. The luciferase–GFP dual-reporter A20-luc configuration enables weekly whole-body bioluminescence in vivo and single-cell tracking in vitro. Pharmacologically, the model carries exceptional validation breadth: anti-PD-1 at 250 µg intraperitoneally (alone or combined with oncolytic vaccinia) slows flank tumors; second-generation anti-CD19 CAR-T cells eliminate established systemic A20 and reveal dose-dependent acute cytokine toxicity and chronic granulomatous sequelae; idiotype vaccines with RNA adjuvant cure pre-established disease; CD19/CD3 bispecific-induced cytokine release and graft-versus-lymphoma activity have been characterized in it; and spleen-homing lipid nanoparticles generating CAR-T cells in situ have been benchmarked against A20-luc — making this single BALB/c line a comprehensive immunotherapy testbed.

Cell Line Information: A20 / A20-luc

A20 (ATCC TIB-208; RRID CVCL_1940) grows in suspension in vitro in RPMI-1640 with 10% fetal bovine serum and 0.05 mM 2-mercaptoethanol, ideally maintained between 1 × 10⁵ and 1 × 10⁶ cells/mL, and its surface immunoglobulin expression is notably medium-dependent — abundant in RPMI-1640 but minimal in Click's medium, a detail that matters when antigen-density-sensitive constructs are being validated. The line is BSL-1, transfectable, and negative for ectromelia virus. The A20-luc variant co-expresses firefly luciferase and EGFP from a lentiviral construct, enabling both bioluminescence imaging in vivo and flow cytometric identification in vitro; an ovalbumin-expressing derivative (A20-OVA) is available for antigen-specific immunity studies.

Our Services

A syngeneic immunotherapy study succeeds or fails on preconditioning logic, reporter consistency, and toxicity vigilance. Alfa Cytology runs A20 programs with monoclonal luciferase–GFP banks whose surface immunoglobulin and MHC-II expression are verified per batch, configurable cyclophosphamide or irradiation preconditioning matched to the cell therapy format, scheduled bioluminescence staging in vivo, and safety monitoring that explicitly includes serum cytokine panels and early hind-limb-paralysis surveillance — the humane-endpoint detail that distinguishes experienced lymphoma operators.

Workflow of A20 / A20-luc Orthotopic Mouse Model Construction

A20 model construction follows compact, highly standardized protocols honed by decades of syngeneic immunotherapy research. The workflow below covers configuration selection, inoculation, imaging-guided staging, and immunotherapy execution with safety-aware endpoints.

1. Cell Expansion and Quality Control: A20 or A20-luc cells are expanded in vitro in RPMI-1640 + 10% FBS + 0.05 mM 2-mercaptoethanol within the 1 × 10⁵–10⁶/mL window; batches are confirmed mycoplasma-negative, STR-authenticated, and verified for surface immunoglobulin, CD19/CD20, and MHC-II expression, with monoclonal luciferase–GFP populations confirmed by in vitro luminescence and fluorescence assays.
2. Configuration and Preconditioning Design: The disease configuration is selected — subcutaneous flank (2 × 10⁵–5 × 10⁶ cells in ~100 µL), intravenous systemic (5 × 10⁵–10⁶ cells in 100 µL), or intraperitoneal — and, where cell therapy or rapid engraftment designs require it, mice receive cyclophosphamide at 100–200 mg/kg intravenously or 1–4 Gy total-body irradiation one day before tumor inoculation.
3. Host Selection and Inoculation: Female BALB/c mice, 6–8 weeks of age, are acclimatized and health-screened; cells are washed twice in cold PBS and administered via tail vein, flank, or intraperitoneal route with implantation day recorded for the treatment calendar.
4. Engraftment Verification and Randomization: Systemic disease is confirmed by whole-body bioluminescence imaging in vivo (100 µL of 30 mg/mL D-luciferin intraperitoneally) at days 7–14, once flux exceeds background in the great majority of animals; flank tumors are staged by caliper, and mice are randomized into vehicle and treatment arms with matched starting burdens.
5. Treatment Administration: Test articles are dosed on study-defined schedules — checkpoint antibodies (for example, anti-PD-1 at 250 µg intraperitoneally on days 7, 10, 14, 17, 21, and 24), CAR-T or CAR-NK cells (typically 3–6 × 10⁶ cells intravenously with defined CD4/CD8 ratios), bispecific engagers, vaccines, or LNP-based in situ CAR formulations.
6. Longitudinal Imaging and Safety Monitoring: Tumor burden is imaged weekly in vivo and quantified as total flux; body weight, posture, and gait are checked daily with explicit surveillance for hind-limb paralysis signaling meningeal invasion, and serial serum is collected for cytokine panels (GM-CSF, IFN-γ, IL-6, TNF-α) where cytokine-release toxicity is a study endpoint.
7. Survival Follow-Up and Rechallenge: Animals are followed for 60–100 days with Kaplan–Meier analysis; long-term survivors may be rechallenged with fresh A20 cells to assess memory immunity, mirroring published curative regimens.
8. Endpoint Analysis and Reporting: At termination or humane endpoint, spleen, liver, bone marrow, and lymph nodes are harvested for enumeration of residual lymphoma and immune populations by flow cytometry (including CAR-positive T cells, CD4/CD8 ratios, regulatory T cells, and CD11b⁺Gr-1⁺ myeloid cells), tissues are processed for H&E and CD3 immunohistochemistry (including toxicity-associated granuloma assessment), ex vivo organ imaging confirms signal distribution, and imaging, cytokine, flow cytometry, and survival data are compiled into the final report.

Fig 2. A20 / A20-luc orthotopic mouse model construction workflow.

Case Study-A20 / A20-luc Orthotopic Mouse Model Development

The A20 platform is among the most cited syngeneic systems in immunotherapy research, and it has carried a broad range of Alfa Cytology client programs — checkpoint blockade alone and in combination with oncolytic agents, anti-CD19 CAR-T benchmarking including toxicity characterization, bispecific engager and cytokine-release studies, therapeutic vaccination with curative readouts, and preconditioning optimization for adoptive cell formats. Across these programs, readouts have combined longitudinal bioluminescence in vivo, serum cytokine kinetics, flow cytometric immune profiling, and long-horizon survival analysis with rechallenge. Anonymized case summaries and representative deliverable formats are available on request.

Why Choose Alfa Cytology?

A20 is a versatile line whose different immunotherapy readouts each demand specific operational discipline. Alfa Cytology has organized its lymphoma service around those distinct demands.

• A fully immunocompetent syngeneic B-cell lymphoma with authentic PD-L1, IL-10, and TGF-β biology for credible checkpoint and combination studies.
• A complete B-cell antigen profile — CD19, CD20, surface immunoglobulin, and MHC-II — supporting CAR, BiTE, vaccine, and radioimmunotherapy formats from one cell bank.
• Monoclonal luciferase–GFP banks with per-batch verification of surface Ig and MHC-II, the antigen-density attributes that cell therapies depend on.
• Configurable preconditioning (cyclophosphamide 100–200 mg/kg or 1–4 Gy TBI) matched to each cell therapy or vaccine design.
• Documented dissemination including meningeal invasion, with hind-limb-paralysis surveillance embedded in humane-endpoint protocols.
• Decades of published benchmarks — from anti-PD-1 schedules to CAR-T cures — available as built-in reference arms.
• Toxicity-aware readouts: serum cytokine panels, CD3 histopathology with granuloma assessment, and CD11b⁺Gr-1⁺ myeloid profiling.

Contact Us

If your immunotherapy program needs a syngeneic lymphoma that can host checkpoint antibodies, CAR constructs, bispecifics, and vaccine strategies alike, the A20 / A20-luc orthotopic model is the field's workhorse — and Alfa Cytology runs it with the preconditioning logic and safety vigilance these studies demand. Contact us to discuss route and preconditioning configurations, engineered variant options, and toxicity endpoint panels, and receive a customized study quotation today.

For research use only. Not intended for any clinical use.